Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Berger Disease Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
sparsentan, irbesartan, Dapagliflozin
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
40
States / cities
Birmingham, Alabama • Homewood, Alabama • Glendale, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Sefaxersen (RO7434656), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Alabaster, Alabama • Birmingham, Alabama • Surprise, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00498368
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

NCT05174221
View directory record Official record
Conditions
Kidney Disease, Glomerulonephritis
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Northridge, California • Nampa, Idaho • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

NCT02384317
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
CCX168
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Palo Alto, California • San Francisco, California • Reno, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
14
States / cities
Glendale, Arizona • San Diego, California • San Dimas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting No phase listed Observational

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

NCT01802034
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

NCT01838239
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, Healthy Subjects
Interventions
Fish Oil
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
Povetacicept
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Enrolling by invitation Phase 2 Interventional

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

NCT06674577
View directory record Official record
Conditions
IgA Nephropathy (IgAN), Renal and Urinary Disorders, Berger Disease
Interventions
Atacicept 150 mg
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional

Atacicept in Subjects With IgA Nephropathy

NCT04716231
View directory record Official record
Conditions
IgA Nephropathy, Berger Disease
Interventions
Atacicept, Placebo to match Atacicept
Biological · Other
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

NCT05200871
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Interventions
Not listed
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Belmar, New Jersey • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827
View directory record Official record
Conditions
Kidney Disease
Interventions
Mezagitamab, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
40
States / cities
Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

NCT02112838
View directory record Official record
Conditions
IGA Nephropathy
Interventions
Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Augusta, Georgia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

NCT05856760
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

NCT03945318
View directory record Official record
Conditions
IgA Nephropathy
Interventions
BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses, Placebo Multiple Doses
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
9
States / cities
Northridge, California • Denver, Colorado • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

NCT00318474
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Mycophenolate Mofetil (MMF), MMF Placebo, ACEi, FOS
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
7 Years to 70 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT07498335
View directory record Official record
Conditions
Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Interventions
Drug: Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

NCT00446459
View directory record Official record
Conditions
Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
Interventions
mycophenolate mofetil (CellCept)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Jul 22, 2026, 2:08 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Sibeprenlimab 400 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 2:08 PM EDT
Completed No phase listed Observational

Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis

NCT00004305
View directory record Official record
Conditions
IGA Glomerulonephritis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

NCT07541287
View directory record Official record
Conditions
IgA Nephropathy
Interventions
JADE101
Drug
Lead sponsor
Jade Biosciences, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Chula Vista, California • Arvada, Colorado • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 2:08 PM EDT